The clinical efficacy of perioperative inhalation of budesonide/formoterol fumarate dehydrate for lung cancer patients with COPD.

The clinical efficacy of perioperative inhalation of budesonide/formoterol fumarate dehydrate for lung cancer patients with COPD. - The clinical efficacy of perioperative inhalation of budesonide/formoterol fumarate dehydrate for lung cancer patients with COPD.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011773

Enrollment

Registered

2013-09-17

Start date

2013-09-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer patients with chronic obstructive pulmonary disease

Interventions

Tiotropium inhalation once daily Tiotropium once daily with budesonide / formoterol combination drug 2 inhalation twice a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Lung cancer patients with COPD(FEV1/FVC<70% in stage I-III) 2) Patients who is scheduled for a standard surgery for lung cancer with clinical stage IA-IIB.

Exclusion criteria

Exclusion criteria: 1) Patients with central lung cancer, wider atelectasis and tumor diameters more than 5cm 2) Patients with known history of asthma or chronic respiratory disease other than COPD, or a recent respiratory tract infection. 3) Patients receiving regular supplement oxygen or corticosteroid, or who had a significant concurrent disease other than COPD. 4) Case who judged doctor in charge targets and it is improper

Design outcomes

Primary

Measure	Time frame
Lung function	—

Secondary

Measure	Time frame
QOL and CT or MRI	—

Countries

Japan

Contacts

Public ContactHidemi Suzuki

Chiba University Graduate School of Medicine Department of General Thoracic Surgery

hidemisuzukidesu@yahoo.co.jp043-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026